Eyepoint study results for vision treatment disappoint, but company still sees promise

Source Summary

Eyepoint reported that patients receiving its experimental treatment for wet age-related macular degeneration (AMD) failed to maintain vision with less frequent injections compared to standard treatment. Despite the disappointing results, the company maintains an optimistic outlook on the therapy.